Mohammed Khalil Mohsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohammed Khalil Mohsen has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alaa Rahhal
Department of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
1 shared publication - Amer Hussein Aljundi
Pharmacy Department, Hamad Medical Corporation, Doha, Qatar
1 shared publication - Fadi Khir
Internal Medicine Residency Program, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
1 shared publication - Jassim Al Suwaidi
Hamad Medical Corporation, Doha, Qatar
1 shared publication - Mohammad Adam
Internal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
1 shared publication
Latest Publications
- Open Access
- 19 April 2020
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 20 (1) , 1-5
Low dose combined oral contraceptives induced thrombotic anterior wall myocardial infarction: a case report
Background: Combined oral contraceptive pills are associated with an established risk for venous thrombosis; however, their risk for arterial thrombosis remains uncertain, especially with the development of low dose new generations of combined oral contraceptive. Arterial thrombosis is less likely to occur with the use of oral contraceptive pills in the absence of cardiovascular risk factors. Case presentation: We report a 35-year old female with no cardiovascular risk factors who presented with thrombotic anterior wall myocardial infarction 6 months after using a third generation low dose combined oral contraceptive pills (Marvelon; ethinylestradiol 30 mcg and desogestrel 150 mcg). Conclusion: Third generation low dose combined oral contraceptives may lead to myocardial infarction in young women, even in the absence of other cardiovascular risk factors.
- 19 April 2020
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 20 (1) , 1-5
Open AccessLow dose combined oral contraceptives induced thrombotic anterior wall myocardial infarction: a case report
Background: Combined oral contraceptive pills are associated with an established risk for venous thrombosis; however, their risk for arterial thrombosis remains uncertain, especially with the development of low dose new generations of combined oral contraceptive. Arterial thrombosis is less likely to occur with the use of oral contraceptive pills in the absence of cardiovascular risk factors. Case presentation: We report a 35-year old female with no cardiovascular risk factors who presented with thrombotic anterior wall myocardial infarction 6 months after using a third generation low dose combined oral contraceptive pills (Marvelon; ethinylestradiol 30 mcg and desogestrel 150 mcg). Conclusion: Third generation low dose combined oral contraceptives may lead to myocardial infarction in young women, even in the absence of other cardiovascular risk factors.